Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01277510 · ClinicalTrials.gov registry record · Phase 3

Pediatric Chronic Kidney Disease Safety and Efficacy

A Phase 3 study, sponsored by Amgen.

Terminated
Registry status
Phase 3
Development phase
43
Enrollment target

NCT01277510 is a Phase 3 study that was terminated before completion, run by Amgen. The registered enrollment target is 43 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01277510, a Phase 3 study, was terminated before completion, sponsored by Amgen.

TERMINATED
Registry status
Phase 3
Development phase
43 participants
Enrollment target

Study Summary

The purpose of this study is to assess the safety and efficacy of adding cinacalcet to the current treatment of secondary hyperparathyroidism in children currently receiving dialysis compared to a treatment regimen that does not include cinacalcet.

Interventions

  • DRUG placebo
  • DRUG Standard of Care
  • DRUG cinacalcet capsule

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2011-06-28
Phase Phase 3

Sponsor

Amgen

558 total trials

What the Registry Record Tells You About NCT01277510

The ClinicalTrials.gov registry entry for NCT01277510 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.

NCT01277510 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01277510 about?

NCT01277510 is a clinical study titled "Pediatric Chronic Kidney Disease Safety and Efficacy". The purpose of this study is to assess the safety and efficacy of adding cinacalcet to the current treatment of secondary hyperparathyroidism in children currently receiving dialysis compared to a treatment regimen that does not include cinacalcet.

What is the current status of trial NCT01277510?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 43 participants. The study started on 2011-06-28.

What interventions are being tested in trial NCT01277510?

The interventions under investigation include: placebo (DRUG), Standard of Care (DRUG), cinacalcet capsule (DRUG).

Who is sponsoring clinical trial NCT01277510?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.